At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 452 enrolled
Drug / intervention
Gabapentin Extended Release tablets +1 moredrug
Likely dose
Gabapentin Extended Release tablets 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia
In Brief
A Phase 3 clinical trial evaluating Gabapentin Extended Release tablets and Placebo for Neuralgia,Postherpetic. Completed, enrolled 452 participants across 39 sites in 3 countries.
Detailed Summary
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia,Postherpetic
CountriesArgentina, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionAug 2009
Study CompletionSep 2009
TodayJul 2026
First PostedMar 14, 2008
Enrollment StartMar 1, 2008
Primary CompletionAug 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.3 years ago
Interventions
Gabapentin Extended Release tabletsdrug
Once-Daily; 300 mg and 600 mg tablets
Placebodrug
Once daily; 300 mg and 600 mg tablets